Insider Buying: NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Director Buys 2,520 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper purchased 2,520 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $18.43 per share, for a total transaction of $46,443.60. Following the transaction, the director now directly owns 3,024,873 shares in the company, valued at approximately $55,748,409.39. This trade represents a 0.08% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock traded up $0.12 during trading on Friday, reaching $18.57. 1,236,945 shares of the company traded hands, compared to its average volume of 713,680. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $27.29. The company has a 50 day moving average price of $18.72 and a 200-day moving average price of $20.72. The firm has a market capitalization of $2.08 billion, a PE ratio of -9.88 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative net margin of 397.45% and a negative return on equity of 37.34%. The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of NAMS. Quarry LP acquired a new position in NewAmsterdam Pharma during the first quarter worth $25,000. GF Fund Management CO. LTD. acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $50,000. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after buying an additional 596 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in NewAmsterdam Pharma by 130.4% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock worth $123,000 after buying an additional 3,390 shares during the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Stifel Nicolaus assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price target on the stock. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research report on Saturday, June 21st. Citigroup assumed coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price target on the stock. Needham & Company LLC restated a "buy" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Cantor Fitzgerald initiated coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 price target on the stock. One investment analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and an average price target of $42.89.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.